KPTI Company Profile and Key Details
Karyopharm Therapeutics Inc.
KPTI Stock Price Chart
Stock Price Today
Karyopharm Therapeutics Inc. (KPTI) stock surged +9.75%, trading at $0.68 on NASDAQ, up from the previous close of $0.62. The stock opened at $0.63, fluctuating between $0.62 and $0.68 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Company Information
| Employees | 325 |
| Beta | 0.15 |
| Sales or Revenue | $146.03M |
| 5Y Sales Change% | 1.393% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Karyopharm Therapeutics Inc. (NASDAQ: KPTI) stock price is $0.68 in the last trading session. During the trading session, KPTI stock reached the peak price of $0.68 while $0.62 was the lowest point it dropped to. The percentage change in KPTI stock occurred in the recent session was 9.75% while the dollar amount for the price change in KPTI stock was $0.06.
The NASDAQ listed KPTI is part of Biotechnology industry that operates in the broader Healthcare sector. Karyopharm Therapeutics Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Mr. Michael J. Mano J.D.
Senior Vice President, Gen. Counsel & Sec.
Sarah Connors
Vice President of Corporation Communications
Mr. Ran Frenkel R.Ph., RPh
Global Head of Clinical Operations
Mr. Pierre S. Sayad M.S., Ph.D.
Vice President of Global Medical & Scientific Affairs
Mr. Richard A. Paulson M.B.A.
Pres, Chief Executive Officer & Director
Dr. Sharon Shacham M.B.A., Ph.D.
Co-Founder & Chairman of Scientific Advisory Board
Mr. Michael P. Mason CPA, M.B.A.
Executive Vice President, Chief Financial Officer & Treasurer
Ms. Sohanya Cheng M.B.A.
Executive Vice President & Chief Commercial Officer
Mr. Stuart Poulton
Executive Vice President & Chief Devel. Officer
Dr. Mansoor Raza Mirza M.D.
Clinical Consultant, Member of Scientific Advisory Board & Independent Director
Mr. Cameron Peters
Vice President of Fin., Assistant Treasurer & Principal Accounting Officer
Ms. Elhan Webb C.F.A.
Senior Vice President of Investor Relations
Mr. James Accumanno J.D.
Chief Compliance Officer
KPTI's closing price is 6.66% higher than its 52-week low of $0.58 where as its distance from 52-week high of $1.70 is -68.22%.
Number of KPTI employees currently stands at 325.
Official Website of KPTI is: https://www.karyopharm.com
KPTI could be contacted at phone 617 658 0600 and can also be accessed through its website. KPTI operates from 85 Wells Avenue, Newton, MA 02459, United States.
KPTI stock volume for the day was 587.09K shares. The average number of KPTI shares traded daily for last 3 months was 902.27K.
The market value of KPTI currently stands at $85.82M with its latest stock price at $0.68 and 126.19M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com